1. Home >
  2. M&A >
  3. Stake Purchase >
  4. China >
  5. CR Pharmaceutical Invests In China Shenghuo Pharmaceutical Holdings

Investment Summary

CR Pharmaceutical Invests In China Shenghuo Pharmaceutical Holdings

On December 9, 2019, CR Pharmaceutical invested in life science company China Shenghuo Pharmaceutical Holdings

Investment Highlights
  • This is CR Pharmaceutical’s 1st transaction in the Life Science sector.
  • This is CR Pharmaceutical’s 1st transaction in China.

Investment Summary
Date 2019-12-09
Target China Shenghuo Pharmaceutical Holdings
Sector Life Science
Investor(s) CR Pharmaceutical
Deal Type Stake Purchase

Target

China Shenghuo Pharmaceutical Holdings

Kunming, China
China Shenghuo Pharmaceutical Holdings is a pharmaceutical group specialized in the field of Traditional Chinese Medicine (TCM). Shenghuo’s flagship product, the XueSaiTong (XST) Soft Capsule, is used to treat cardiovascular diseases and is made from a precious Chinese herb known as Sanchi combined with modern pharmaceutical methods. China Shenghuo Pharmaceutical Holdings was founded in 1995 and is based in Kunming, China.

Search 214,744 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

CR Pharmaceutical

Shenzhen , China
Category Company
Founded 1999
Sector Life Science
Employees20,031
Revenue 27.6B CNY (2024)
DESCRIPTION

CR Pharmaceutical is a integrated pharmaceutical company specializing in R&D, manufacturing, distribution, and retail of medicines and nutraceutical products. CR Pharmaceutical was founded in 1999 and is based in Shenzhen, China.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Stake Purchase M&A Deals 1 of 1
Country: China M&A 1 of 1
Year: 2019 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal